Lupin gets these 7 observations from USFDA for Goa Plant

The US health regulator carried the inspection between September 10 to September 18, 2021, and closed with seven observations.

350
USFDA
Picture: Pixabay

Last Updated on September 24, 2021 by The Health Master

Pharma-major Lupin has received seven observations from the USFDA after the latter carried an inspection at the company’s Goa facility in India.

The US health regulator carried the inspection between September 10 to September 18, 2021, and closed with seven observations.

Lupin said that “We are confident of addressing the observations satisfactorily and are committed to be compliant with Good Manufacturing Practice standards across all our facilities.”

At around 10.42 am, Lupin was trading at Rs 939.40 per piece down by 1.2% on Sensex.

The stock has touched an intraday high and low of Rs 941.30 per piece and Rs 913 per piece respectively. 

The observations received by the company are as follows:

  • Investigations of an unexplained discrepancy did not extend to other drug products that may have been associated with the specific failure or discrepancy.
  • In process, materials are not tested for strength and approved or rejected by the quality control unit during the production process.
  • Examination and testing of samples did not assure that the drug product and in-process material conformed to specification.
  • Establishment of the reliability of component supplier’s report of analysis is deficient in that the test results are not appropriately validated at appropriate intervals.
  • The procedures for annual quality standards record evaluation are deficient in that they do not address a review of returned drug product records for each drug product.
  • The written stability programme is not followed.
  • Access to the storage area for labels and labelling materials is not limited to authorised personnel.

Inputs from Express Pharma also added

USFDA inspection ends with ‘Zero’ observations: Alkem

Alkem gets two observations from USFDA for USA plant

Dr Reddy’s gets 3 observations from USFDA for US-based API plant

Alembic Pharma gets 5 observations from USFDA

Lupin gets 13 observations post USFDA inspection

USFDA issues 9 observations to Aurobindo Pharma

Gujarat launched Online portal for Drug Manufacturing License

Govt begins Anti Dumping probe: Ofloxacin & its intermediates imported…

India to get Johnson & Johnson vaccine doses next month

Covaxin kids trial over: Data to be submitted to DCGI

India and Pharmacy Education: Chapter: 8

Latest Notifications regarding Pharmaceuticals

Telegram
WhatsApp
Facebook
LinkedIn
Google-news

Enter your email address:

Delivered by FeedBurner